Takeda Expands its Collaboration with Finch Therapeutics to Develop Microbiome Therapies Utilizing Human-First Discovery Platform

 Takeda Expands its Collaboration with Finch Therapeutics to Develop Microbiome Therapies Utilizing Human-First Discovery Platform

Takeda Expands its Collaboration with Finch Therapeutics to Develop Microbiome Therapies Utilizing Human-First Discovery Platform

Shots:

  • Finch and Takeda will leverage Finch’s platform to develop microbiome-based therapeutics targeting Crohn’s disease. Takeda to get exclusive worldwide rights to commercialize rationally selected microbiota (RSM) therapies developed for Crohn’s disease
  • In 2107, Takeda and Finch collaborated to jointly develop FIN-524 for ulcerative colitis under which Finch has received $10M upfront, milestones & royalties on global sales while Takeda got exclusive worldwide rights to develop and commercialize FIN-524 and rights to follow-on products in IBD
  • Finch’s human-first discovery platform allows the development of full-spectrum microbiota (FSM) therapies comprising a diverse community of microbiota from human donors as well as RSM therapies containing select bacterial strains, grown in pure culture in human microbiota transplantation studies

Click here to­ read full press release/ article | Ref: Businesswire | Image: Hines

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post